Table 1. Comparative summary statistics for demographic, clinical and laboratory data.

	Nevirapine-based HAART (n = 89)	Efavirenz-based HAART (n = 30)	P-value
Age in years	31.4 (28.3–36.5)	32.6 (28.9–37.7)	0.258
Female	81 (91%)	25 (83%)	0.200
CDC stage B or C	30 (34%)(n = 88)	13 (46%)(n = 28)	0.267
CD4 count (cells/mm3)	241 (173–359)	159 (110–265)	0.005
HIV RNA (log10 copies/mL)	3.70 (3.28–4.09)	3.99 (3.75–4.69)	0.007
CRF01_AE	84 (94%)	29 (97%)
Exposure to single-dose nevirapine	58 (81%)	10 (56%)	0.036
Time (days) from single-dose nevirapine to HAART initiation	139 (64–397)	387 (125–505)	0.299
ZDV backbone	20(22%)	15(50%)	0.006
d4T backbone	60(67%)	5(17%)	<0.001
TDF backbone	9(10%)	10(33%)	0.007
3TC backbone	82(92%)	19(63%)	<0.001
FTC backbone	7(8%)	10(33%)	0.001
Estimated duration (days) of virologic failure before HIV resistance genotype testing	91 (42–189)	93 (56–196)	0.743
Time (days) from HAART initiation to virologic failure	238 (112–609)	212 (88–441)	0.530

All figures are medians (interquartile ranges) or number (percent).